

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT8389692

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
GANYMED PHARMACEUTICALS GMBH	03/27/2023
RECEIVING PARTY DATA	
Name:	ASTELLAS PHARMA INC.
Street Address:	5-1, NIHONBASHI-HONCHO 2-CHOME CHUO-KU
City:	TOKYO
State/Country:	JAPAN
Postal Code:	103-8411
PROPERTY NUMBERS Total: 1	
Property Type	Number
Patent Number:	9932401
CORRESPONDENCE DATA	
Fax Number:	
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	312-269-5358
Email:	hrawl@nge.com
Correspondent Name:	KEVIN A. O'CONNOR
Address Line 1:	2 NORTH LASALLE STREET
Address Line 2:	SUITE 1700
Address Line 4:	CHICAGO, ILLINOIS 60602
ATTORNEY DOCKET NUMBER:	026156-8007
NAME OF SUBMITTER:	KEVIN A. O'CONNOR
SIGNATURE:	/Kevin A. O'Connor/
DATE SIGNED:	01/19/2024
Total Attachments: 2	
source=US NGE - Ganymed - Assignment#page1.tif	
source=US NGE - Ganymed - Assignment#page2.tif	

ASSIGNMENT

WHEREAS, Ganymed Pharmaceuticals GmbH, a German Corporation, with offices at An der Goldgrube 12, 55131 Mainz, Germany (Assignor) owns the entire right, title and interest in and to the following patents and patent applications listed in the Schedule A attached hereto;


AND, WHEREAS, Astellas Pharma Inc., a Japanese Corporation, with offices at 5-1, Nihonbashi-Honcho 2-Chome Chuo-ku, Tokyo 103-8411, Japan (Assignee), is desirous of acquiring the entire right, title and interest in and to said improvements in and to said patent applications, all patent rights therefor, and the right to sue for past infringement.

Now, therefore, for good and valuable consideration, the receipt whereof is acknowledged, Assignor confirms that it has assigned and transferred, and by these presents does hereby assign and transfer, to the Assignee the entire right, title and interest in and to all said patent applications (including, but not limited to, divisional applications, continuation applications, continuation-in-part applications derived therefrom) and patents that arise therefrom, including, without limitation, the full right to claim for any such subsequent application all benefits and priority rights under any applicable convention, together with the entire right, title and interest in and to all said patents, including any and all reissue patents derived therefrom, including, without limitation, the right to sue for past infringement; to have and to hold for sole and exclusive use and benefit of the Assignee, its successors and assigns, to the full end of the term or terms for all such patents.

Ganymed Pharmaceuticals GmbH

Date: March 27, 2023

By:



Name: Kevin D. Miles

Title: General Manager

**SCHEDULE A
PATENT LIST**

Country	Application Date	Application No.	Patent No.	Title
US	19.02.2010	16/275111	11473085	Methods and Compositions For Diagnosis and Treatment of Cancer
US	19.02.2010	17/821997		Methods and Compositions For Diagnosis and Treatment of Cancer
US	11.11.2010	15/133783	9932401	Antibodies Specific For Claudin 6 (CLDN6)
US	11.11.2010	15/885454	10745477	Antibodies Specific For Claudin 6 (CLDN6)
US	11.11.2010	16/922179		Antibodies Specific For Claudin 6 (CLDN6)
US	20.04.2012	16/028210	10919974	Antibodies For Treatment of Cancer Expressing Claudin 6
US	20.04.2012	17/138403		Antibodies For Treatment of Cancer Expressing Claudin 6
US	19.02.2020	16/795,468		Diagnosis and Therapy of Cancer Involving Cancer Stem Cells

Appendix-1